🚀 VC round data is live in beta, check it out!
Gyre Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gyre Therapeutics and similar public comparables like Basilea Pharmaceutica, CytomX Therapeutics, Strides Pharma, Marksans Pharma and more.
Gyre Therapeutics Overview
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Founded
1997
HQ
Employees
579
Website
Sectors
Financials (LTM)
EV
$783M
Gyre Therapeutics Financials
Gyre Therapeutics reported last 12-month revenue of $121M and EBITDA of $5M.
In the same LTM period, Gyre Therapeutics generated $115M in gross profit, $5M in EBITDA, and had net loss of ($2M).
Revenue (LTM)
Gyre Therapeutics P&L
In the most recent fiscal year, Gyre Therapeutics reported revenue of $106M and EBITDA of $18M.
Gyre Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $121M | XXX | $106M | XXX | XXX | XXX |
| Gross Profit | $115M | XXX | $102M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | $5M | XXX | $18M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | ($2M) | XXX | $12M | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gyre Therapeutics Stock Performance
Gyre Therapeutics has current market cap of $841M, and enterprise value of $783M.
Market Cap Evolution
Gyre Therapeutics' stock price is $8.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $783M | $841M | 0.0% | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGyre Therapeutics Valuation Multiples
Gyre Therapeutics trades at 6.5x EV/Revenue multiple, and 151.3x EV/EBITDA.
EV / Revenue (LTM)
Gyre Therapeutics Financial Valuation Multiples
As of March 18, 2026, Gyre Therapeutics has market cap of $841M and EV of $783M.
Equity research analysts estimate Gyre Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gyre Therapeutics has a P/E ratio of (505.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $841M | XXX | $841M | XXX | XXX | XXX |
| EV (current) | $783M | XXX | $783M | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | 151.3x | XXX | 43.9x | XXX | XXX | XXX |
| EV/EBIT | 306.3x | XXX | 48.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | 7.7x | XXX | XXX | XXX |
| P/E | (505.1x) | XXX | 69.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (115.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gyre Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gyre Therapeutics Margins & Growth Rates
Gyre Therapeutics' revenue in the last 12 month grew by 13%.
Gyre Therapeutics' revenue per employee in the last FY averaged $0.2M.
Gyre Therapeutics' rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gyre Therapeutics' rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gyre Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | (476%) | XXX | (36%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 54% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | 15% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gyre Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Basilea Pharmaceutica | XXX | XXX | XXX | XXX | XXX | XXX |
| CytomX Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Strides Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Marksans Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Chong Kun Dang Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gyre Therapeutics M&A Activity
Gyre Therapeutics acquired XXX companies to date.
Last acquisition by Gyre Therapeutics was on XXXXXXXX, XXXXX. Gyre Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gyre Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGyre Therapeutics Investment Activity
Gyre Therapeutics invested in XXX companies to date.
Gyre Therapeutics made its latest investment on XXXXXXXX, XXXXX. Gyre Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gyre Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gyre Therapeutics
| When was Gyre Therapeutics founded? | Gyre Therapeutics was founded in 1997. |
| Where is Gyre Therapeutics headquartered? | Gyre Therapeutics is headquartered in United States. |
| How many employees does Gyre Therapeutics have? | As of today, Gyre Therapeutics has over 579 employees. |
| Who is the CEO of Gyre Therapeutics? | Gyre Therapeutics' CEO is Ping Zhang. |
| Is Gyre Therapeutics publicly listed? | Yes, Gyre Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Gyre Therapeutics? | Gyre Therapeutics trades under GYRE ticker. |
| When did Gyre Therapeutics go public? | Gyre Therapeutics went public in 2023. |
| Who are competitors of Gyre Therapeutics? | Gyre Therapeutics main competitors are Basilea Pharmaceutica, CytomX Therapeutics, Strides Pharma, Marksans Pharma. |
| What is the current market cap of Gyre Therapeutics? | Gyre Therapeutics' current market cap is $841M. |
| What is the current revenue of Gyre Therapeutics? | Gyre Therapeutics' last 12 months revenue is $121M. |
| What is the current revenue growth of Gyre Therapeutics? | Gyre Therapeutics revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Gyre Therapeutics? | Current revenue multiple of Gyre Therapeutics is 6.5x. |
| Is Gyre Therapeutics profitable? | Yes, Gyre Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gyre Therapeutics? | Gyre Therapeutics' last 12 months EBITDA is $5M. |
| What is Gyre Therapeutics' EBITDA margin? | Gyre Therapeutics' last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Gyre Therapeutics? | Current EBITDA multiple of Gyre Therapeutics is 151.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.